Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Loa Loa (eye worm) | hypothetical protein | 0.0351 | 1 | 1 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0345 | 0.9706 | 0.9706 |
Onchocerca volvulus | 0.0351 | 1 | 0.5 | |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0351 | 1 | 1 |
Trypanosoma brucei | 6-phosphofructo-2-kinase 2 | 0.0345 | 0.9706 | 0.9706 |
Mycobacterium ulcerans | fructose-2,6-bisphosphatase GpmB | 0.0207 | 0.2852 | 0.5 |
Giardia lamblia | Hypothetical protein | 0.0207 | 0.2852 | 0.5 |
Schistosoma mansoni | 6-phosphofructokinase | 0.0351 | 1 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase 1 | 0.0345 | 0.9706 | 0.9706 |
Giardia lamblia | Hypothetical protein | 0.0207 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0351 | 1 | 1 |
Entamoeba histolytica | phosphoglycerate mutase family protein, putative | 0.0207 | 0.2852 | 0.5 |
Mycobacterium ulcerans | hypothetical protein | 0.0207 | 0.2852 | 0.5 |
Trypanosoma cruzi | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0351 | 1 | 1 |
Leishmania major | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0345 | 0.9706 | 0.9706 |
Trypanosoma brucei | 6-phosphofructo-2-kinase/fructose-2,6-biphosphatase, putative | 0.0351 | 1 | 1 |
Loa Loa (eye worm) | hypothetical protein | 0.0345 | 0.9706 | 0.9604 |
Echinococcus multilocularis | 6 phosphofructo 2 kinase:fructose 2 | 0.0351 | 1 | 0.5 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
GI (functional) | = 4 % | Cytotoxicity against human KB cells assessed as growth inhibition at 10 '-6 M after 72 hrs by MTS assay | ChEMBL. | 22257529 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.